Skip to content
DataLookout
Menu

NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 364 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026
  2. Minor Start date: Nov 3, 2026 to Nov 4, 2026
  3. Minor Start date: Nov 2, 2026 to Nov 3, 2026
  4. Minor Start date: Nov 1, 2026 to Nov 2, 2026
  5. Minor Start date: Oct 29, 2026 to Nov 1, 2026
Show 45 earlier versionsHide 45 earlier versions
  1. Minor Start date: Oct 28, 2026 to Oct 29, 2026
  2. Minor Start date: Oct 27, 2026 to Oct 28, 2026
  3. Minor Start date: Oct 26, 2026 to Oct 27, 2026
  4. Minor Start date: Oct 25, 2026 to Oct 26, 2026
  5. Minor Start date: Oct 22, 2026 to Oct 25, 2026
  6. Minor Start date: Oct 21, 2026 to Oct 22, 2026
  7. Minor Start date: Oct 20, 2026 to Oct 21, 2026
  8. Minor Start date: Oct 19, 2026 to Oct 20, 2026
  9. Minor Start date: Oct 18, 2026 to Oct 19, 2026
  10. Minor Start date: Oct 14, 2026 to Oct 18, 2026
  11. Minor Start date: Oct 13, 2026 to Oct 14, 2026
  12. Minor Start date: Oct 12, 2026 to Oct 13, 2026
  13. Notable Eligibility criteria expanded, about 16 words
    • Start date: Oct 11, 2026 to Oct 12, 2026
    • Study description shortened, about 4 words
  14. Minor Start date: Oct 8, 2026 to Oct 11, 2026
  15. Minor Start date: Oct 7, 2026 to Oct 8, 2026
  16. Minor Start date: Oct 6, 2026 to Oct 7, 2026
  17. Minor Start date: Oct 5, 2026 to Oct 6, 2026
  18. Minor Start date: Oct 4, 2026 to Oct 5, 2026
  19. Minor Start date: Sep 20, 2026 to Oct 4, 2026
  20. Minor Start date: Sep 17, 2026 to Sep 20, 2026v340
  21. Minor Start date: Sep 16, 2026 to Sep 17, 2026v339
  22. Minor Start date: Sep 15, 2026 to Sep 16, 2026v338
  23. Minor Start date: Sep 14, 2026 to Sep 15, 2026v337
  24. Minor Start date: Sep 10, 2026 to Sep 14, 2026v336
  25. Minor Start date: Sep 9, 2026 to Sep 10, 2026v335
  26. Minor Start date: Sep 8, 2026 to Sep 9, 2026v334
  27. Minor Start date: Sep 7, 2026 to Sep 8, 2026v333
  28. Minor Start date: Sep 6, 2026 to Sep 7, 2026v332
  29. Minor Start date: Sep 3, 2026 to Sep 6, 2026v331
  30. Minor Start date: Sep 2, 2026 to Sep 3, 2026v330
  31. Minor Start date: Sep 1, 2026 to Sep 2, 2026v329
  32. Minor Start date: Aug 31, 2026 to Sep 1, 2026v328
  33. Minor Start date: Aug 30, 2026 to Aug 31, 2026v327
  34. Minor Start date: Aug 27, 2026 to Aug 30, 2026v326
  35. Minor Start date: Aug 26, 2026 to Aug 27, 2026v325
  36. Minor Start date: Aug 25, 2026 to Aug 26, 2026v324
  37. Minor Start date: Aug 24, 2026 to Aug 25, 2026v323
  38. Minor Start date: Aug 23, 2026 to Aug 24, 2026v322
  39. Minor Start date: Aug 20, 2026 to Aug 23, 2026v321
  40. Minor Start date: Aug 19, 2026 to Aug 20, 2026v320
  41. Minor Start date: Aug 18, 2026 to Aug 19, 2026v319
  42. Minor Start date: Aug 17, 2026 to Aug 18, 2026v318
  43. Minor Start date: Aug 16, 2026 to Aug 17, 2026v317
  44. Minor Start date: Aug 13, 2026 to Aug 16, 2026v316
  45. Minor Start date: Aug 12, 2026 to Aug 13, 2026v315
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety
Timeframe: From time of the lymphodepleting chemotherapy through 5 years after neoepitope-specific T cell infusion or until off study.

Secondary (2)

Overall response rate
Feasibility of manufacturing and administering neoepitope-specific T cells

Arms and interventions

1/Experimental: No allo-HSCTExperimental

Preparative regimen of cyclophosphamide and fludarabine + infusion of neoepitope-specific T cells (of up to 1.5x10\^11 total cells) + aldesleukin.

2/Experimental: prior allo-HSCTExperimental

Preparative regimen of cyclophosphamide and fludarabine + infusion of neoepitope-specific T cells (at a dose of 1x10\^10 total cells) + aldesleukin.

Drugs: aldesleukin, cyclophosphamide, fludarabine phosphate

Biologicals: Individual Patient TCR-Transduced PBL

Devices: TruSight Oncology (TSO) 500

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States